EMA-approved—NSCLC (advanced/metastatic, EGFR-activating mutations, EGFR exon 19 deletions, EGFR exon 21 (L858R) substitution mutations, and EGFR T790M mutations). This evidence concerns the gene EGFR and non-small cell lung carcinoma.